Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Non-Current Liabilities: 2015-2024

Historic Other Non-Current Liabilities for Spyre Therapeutics (SYRE) over the last 9 years, with Dec 2024 value amounting to $36.6 million.

  • Spyre Therapeutics' Other Non-Current Liabilities fell 91.07% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 91.07%. This contributed to the annual value of $36.6 million for FY2024, which is 11.35% down from last year.
  • As of FY2024, Spyre Therapeutics' Other Non-Current Liabilities stood at $36.6 million, which was down 11.35% from $41.3 million recorded in FY2023.
  • In the past 5 years, Spyre Therapeutics' Other Non-Current Liabilities registered a high of $41.3 million during FY2023, and its lowest value of $16,000 during FY2021.
  • In the last 2 years, Spyre Therapeutics' Other Non-Current Liabilities had a median value of $39.0 million in 2023 and averaged $39.0 million.
  • In the last 5 years, Spyre Therapeutics' Other Non-Current Liabilities spiked by 590.32% in 2020 and then plummeted by 92.52% in 2021.
  • Yearly analysis of 4 years shows Spyre Therapeutics' Other Non-Current Liabilities stood at $214,000 in 2020, then slumped by 92.52% to $16,000 in 2021, then reached $41.3 million in 2023, then decreased by 11.35% to $36.6 million in 2024.